PillRx only · Injection, Solution · Intravenous
Papaverine Hydrochloride
Papaverine Hydrochloride
2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US2 NDCs
2 active makers
2 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
ATC—
RxCUI (US)—
US makers2 labelers
Packages3
DEA / ScheduleNone
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
16
Rx · 2026 Q1
34
Units dispensed
-71%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it2 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Oryza Pharmaceuticals Inc. | unknown | 2 | SUPPLYING |
| American Regent, Inc. | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Mar 14, 2022RECALLRecall (Class II): PAPAVERINE HYDROCHLORIDE Injection, USP, 60 mg/2mL (30 mg/mL), packaged as a) 25 x 2mL Single Use Vials per box (NDC 72…
Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile. — Recalling firm: Vitae Enim Vitae Scientific, Inc. — Nationwide in the U.S.A